Publications
Publications
This range of Verona Pharma-supported publications provide further pharmacologic background to the research that we are engaged in.
Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)
Antonio Anzueto, Igor Z Barjaktarevic, Thomas M Siler, Tara Rheault, Thomas Bengtsson, Kathleen Rickard and Frank Sciurba
American Journal of Respiratory and Critical Care Medicine, August 15, 2023
Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD
James F Donohue, Tara Rheault, Margot MacDonald-Berko, Thomas Bengtsson, Kathleen Rickard
International Journal of Chronic Obstructive Pulmonary Disease, July 28, 2023
A dose-ranging study of the novel inhaled dual PDE 3 and 4 inhibitor ensifentrine in patients with COPD receiving maintenance tiotropium therapy. Study 205.
Gary T Ferguson, Edward M Kerwin, Tara Rheault, Thomas Bengtsson, Kathleen Rickard
International Journal of Chronic Obstructive Pulmonary Disease, April 22, 2021
The phosphodiesterase inhibitor ensifentrine reduces production of pro-inflammatory mediators in well-differentiated bronchial epithelial cells by inhibiting PDE4
Mark Turner, Nurlan Dauletbaev, Larry Lands and John W. Hanrahan
Journal of Pharmacology and Experimental Therapeutics, 4 October 2020
Symptom improvement following treatment with the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in patients with moderate to severe COPD – a detailed analysis
Henrik Watz, Kathleen Rickard, Tara Rheault, Thomas Bengtsson, Dave Singh
International Journal of Chronic Obstructive Pulmonary Disease, 16 September 2020
A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD. Study 203.
Dave Singh, Fernando J. Martinez, Henrik Watz, Thomas Bengtsson, Brian T. Maurer
Respiratory Research, 10 February 2020
Clinical milestones of a candidate COPD treatment
Tara Rheault and Margot Macdonald-Berko
MedNous, July/August 2019
Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma
Leif Bjermer, Katharine Abbott-Banner, Kenneth Newman
Pulmonary Pharmacology & Therapeutics, 14 June 2019, 101814
The short-term bronchodilator effects of the dual PDE3 and PDE4 inhibitor RPL554 in COPD
David Singh, Katharine Abbot-Banner, Thomas Bergtsson, Kenneth Newman
Eur. Respir. J. 2018
Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials
Lui G Franciosi, PhD, Prof. Zuzana Diamant, MD, Katharine H Banner, PhD, Rob Zuiker, MD, Nicoletta Morelli, MD, Ingrid M C Kamerling, PhD, Marieke L de Kam, MSc, Prof. Jacobus Burggraaf, MD, Prof. Adam F Cohen, MD, Prof. Mario Cazzola, et al.
The Lancet Respiratory Medicine, October 25 2013, http://dx.doi.org/10.1016/S2213- 2600(13)70187-5
Dual PDE3/4 and PDE4 Inhibitors: Novel Treatments For COPD and Other Inflammatory Airway Diseases
Katharine H. Abbott-Banner and Clive P. Page
Basic & Clinical Pharmacology & Toxicology Doi: 10.1111/bcpt.12209
A combined Phase I/IIa study of the safety, bronchodilator and bronchoprotective effects of nebulized RPL554, a dual PDE3/4 inhibitor, in healthy subjects and asthmatics
Franciosi L, Diamant Z, Morelli N, de Kam M, Cohen A, Walker M, Page CP.
Clin Transl Allergy. 2013; 3 (Suppl 1): O13
Verona Pharma
Investor Information
© Verona Pharma plc 2023. All rights reserved